Novo Nordisk’s Wegovy (semaglutide), a glucagon-like peptide-1 (GLP-1) receptor agonist, shows better efficacy for weight loss than its peers but it requires a significant discount to be cost-effective, according to a new analysis from the Institute for Clinical and Economic Review (ICER).
Source: Drug Industry Daily